SierraSil® has been subjected to a rigorous level of testing and analysis. From these extensive assessments, experts agree that SierraSil® is safe and effective and promotes joint health and function.*
1. HUMAN CLINICAL STUDY
A multi-center, double-blind, randomized, placebo-controlled study of more than 100 patients needing joint support was conducted at four different servings (three with SierraSil®, one with placebo). This study was published in a peer-reviewed journal.
Internationally Registered, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial #ISRCTN38432711. PUBLISHED: The Journal of Inflammation.
RESULTS: This study provides clear evidence that SierraSil®, at 3 and 2 capsules, may provide some joint support within two weeks of daily use*.
2. MECHANISM OF ACTION STUDY
This test was undertaken to determine how SierraSil® worked on human cartilage in-vitro. The test demonstrated that SierraSil® promoted cartilage health, measured by the reduced amount of degraded cartilage debris, as glycosaminoglycans (GAG) release.*
Miller, Mark J.S., Ahmed, S. et al. 2004. Suppression of Human Cartilage Degradation and Chondrocyte Activation by a Unique Mineral Supplement (SierraSil®) and a Cat’s Claw Extract, Vincaria®. Journal of the American Nutraceutical Association. Vol. 7. No. 2:32-39.
3. HUMAN PILOT STUDY
SierraSil® was tested to determine if it safely provided significant support to knees*.
WOMAC (Western Ontario and McMaster Osteoarthritis Index) scoring.
4. DISSOLUTION TEST (BIOACCESSIBILITY)
A sample of SierraSil® was tested to determine the bioaccessibility of minerals.
RESULTS: The bioaccessibility of aluminum, lead and iron was found to be very low.
Protocol: US Pharmacopeia 24 Method 711
5. SUB-ACUTE ORAL TOXICITY STUDY
A daily serving of SierraSil® up to 1,000 mg/kg (35 times the recommended serving) for a period of 90 days was tested.
RESULTS: SierraSil® did not cause any adverse responses at the highest level taken.
Protocol: OECD No. 408